Table 1 The correlations between circMYO1C levels and PDAC patients’ clinicopathological characteristics.

From: m6A-modified circRNA MYO1C participates in the tumor immune surveillance of pancreatic ductal adenocarcinoma through m6A/PD-L1 manner

  

circMYO1C

p

Low (30)

High (30)

Age

 <60 year

25

14

11

0.432

 ≥60 year

35

16

19

 

Gender

 Male

34

18

16

0.794

 Female

26

12

14

 

TNM stage

 I-II

23

17

6

0.003

 III-IV

37

13

24

 

Differentiation

 Well

11

5

6

0.942

 Moderate

37

19

18

 

 Poor

12

6

6

 

Lymph node metastasis

 No

28

18

10

0.038

 Yes

32

12

20

 
Back to article page